Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ranbaxy Also Could Face Probe By Indian Authorities

This article was originally published in PharmAsia News

Executive Summary

Ranbaxy Laboratories not only faces an investigation in the U.S., it also could become the subject of a probe at home in India. Indian authorities have raised questions about whether Ranbaxy's stockholders were informed about U.S. FDA allegations that the firm marketed adulterated generics. Indian authorities are expected to review the same documents requested by U.S. authorities, to see if the company adequately informed shareholders of the financial risks involved in the investigation. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts